The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol

被引:202
|
作者
Piper, Derek E.
Jackson, Simon
Liu, Qiang
Romanow, William G.
Shetterly, Susan
Thibault, Stephen T.
Shan, Bei
Walker, Nigel P. C. [1 ]
机构
[1] Amgen Inc, Dept Mol Struct, 1120 Vet Blvd, San Francisco, CA 94080 USA
[2] Amgen Inc, Dept Metab Disorders, San Francisco, CA 94080 USA
[3] Amgen Inc, Dept Prot Sci, San Francisco, CA 94080 USA
关键词
D O I
10.1016/j.str.2007.04.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 50 条
  • [1] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [2] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [3] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    [J]. Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [4] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [5] Plasma PCSK9 Levels Are Positively Correlated With LDL-Cholesterol Concentrations in Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Hogue, Jean-Charles
    Ooi, Teik C.
    Lamarche, Benoit
    Couture, Patrick
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [6] Evolocumab (Repatha) A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 139 - 140
  • [7] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [8] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
  • [9] The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
    Feng, Q.
    Wei, W. Q.
    Chung, C. P.
    Levinson, R. T.
    Bastarache, L.
    Denny, J. C.
    Stein, C. M.
    [J]. PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 204 - 208
  • [10] PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer
    Patrono, Carlo
    Volpe, Massimo
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (12) : 1130 - 1131